Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

BACKGROUND/AIMS: Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P in Korean patients with chronic hepatitis C virus...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Jeong, Kim, Yoon Jun, Lee, Jin-Woo, Kim, Ji Hoon, Lim, Young-Suk, Han, Kwang-Hyub, Jeong, Sook-Hyang, Cho, Mong, Yoon, Ki Tae, Bae, Si Hyun, Crown, Eric D., Fredrick, Linda M., Alami, Negar Niki, Asatryan, Armen, Kim, Do Hyun, Paik, Seung Woon, Lee, Youn-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593501/
https://www.ncbi.nlm.nih.gov/pubmed/34053916
http://dx.doi.org/10.5009/gnl20321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593501/
https://www.ncbi.nlm.nih.gov/pubmed/34053916
http://dx.doi.org/10.5009/gnl20321

Ejemplares similares